AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its 2024 annual financial report, initially scheduled for 30 April 2025, to give the auditors time ...
AB SCIENCE announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors Paris, April 27, 2026, 6pm CET AB Science SA (Euronext - ...
AB Science has received a binding offer for a Clinical Trial Funding Insurance policy from Medical & Commercial International Ltd. (MCI), Lloyd’s Syndicate 1902, for its Phase III clinical trial ...
While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are ...
After years of disappointment, things might seem to be looking up for the amyotrophic lateral sclerosis patient community. Two weeks ago they got a new drug approved by the FDA, and now French biotech ...
Analysts have torn into AB Science over the clinical trial compliance failings identified by regulators in France. Oddo took the most extreme action by slashing its price target from €48 ($53) to €5, ...
AB Science S.A. (the " Company ” or " AB Science ”, Euronext - FR0010557264 - AB) announces today the successful completion of a capital increase of a total gross amount of EUR 3.2 million subscribed ...
AB SCIENCE PROVIDES AN UPDATE ON THE MICROTUBULE PROGRAM AB8939 AND IN PARTICULAR THE ABILITY OF AB8939 TO GENERATE RESPONSE ON MECOM REARRANGEMENT AB Science SA (Euronext - FR0010557264 - AB) today ...
French biotech company AB Science has been studying its lead compound, masitinib, for a dozen years, but so far it has only won approval to market the compound to treat dogs with cancer in the U.S.
THE POLICY COVERS UP TO EUR 25 MILLION OF TRIAL COSTS IN THE EVENT OF CLINICAL FAILURE, WITH ZERO DEDUCTIBLE THIS RISK-TRANSFER STRUCTURE PROTECTS SHAREHOLDER CAPITAL AND SIGNALS INSTITUTIONAL ...
THE POLICY COVERS UP TO EUR 25 MILLION OF TRIAL COSTS IN THE EVENT OF CLINICAL FAILURE, WITH ZERO DEDUCTIBLE AB Science has received a binding offer for a Clinical Trial Funding Insurance policy from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results